Skip to content

Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study

Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01953627
Enrollment
150
Registered
2013-10-01
Start date
2012-10-31
Completion date
2014-12-31
Last updated
2014-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological Surgery

Brief summary

Laparoscopic robotic surgery (LSM) seems to increase quality of surgery. Diffusion of LSM is limited by cots of the only available system today. Kymerax® is a cheaper new system of LSM. Aim : To evaluate feasibility of laparoscopy with Kymerax® system in different laparoscopic procedures in gynecology. Material and methods : Observational study. Inclusion criteria were : patient requiring laparoscopic procedure in gynecology who give informed consent. The investigators evaluate procedures routinely performed by laparoscopy in gynecology. Hypothesis : Procedures performed routinely in gynecology were feasible with Kymerax® system.

Interventions

PROCEDURESurgical procedure with the system Kymerax
DEVICEThe system Kymerax

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient requiring a following surgical procedure realized usually by coelioscopy: Total hysterectomy or inter annexielle for mild or neoplastic pathology Promontofixation for genital prolapse Annexectomie or ovarian kystectomie for ovarian pathology Pelvic or lombo-aortic cleaning out for uterine cancer Tubaire Salpingectomie for pathology Rectovaginale partition Exérèse hurts of endometriosis

Exclusion criteria

* Patient refusing to participate in the study * Patient understanding French. * Minor waits

Design outcomes

Primary

MeasureTime frame
assessment of Kymerax systemerax18 months

Countries

France

Contacts

Primary Contactaubert AGOSTINI
aubert.agostini@ap-hm.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026